Companies in #Myelofibrosis
Found 1 company operating in this sector.
Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company pioneering novel cancer therapies, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for oncology indications including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and endometrial cancer through SIENDO/XPORT-EC-042. On November 2, 2026, Karyopharm entered into a Restructuring Support Agreement and filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas to implement a court-supervised sale and merger with Ayrmid Ltd. as the stalking horse bidder, supported by $55 million in committed debtor-in-possession (DIP) financing to maintain ordinary operations, employee payroll, and patient drug supply uninterrupted.